Direct Answer
Based on the GLP-1 Editorial v3.0 transparency rubric, NexLife (score 94/100) ranks higher for compounded semaglutide when scored on the six weighted pillars (clinical protocol, pharmacy transparency, pricing, follow-up, regulatory clarity, patient experience).
The two providers operate different care models. This comparison is for eligible cash-pay patients comparing online compounded semaglutide programs.
Head-to-head: NexLife vs Henry Meds for compounded semaglutide
Both providers operate flat-rate compounded semaglutide programs with physician oversight and patient support. The two structural differences: price level (NexLife $145/mo vs Henry Meds $295/mo on flat-rate plans) and pharmacy disclosure (NexLife discloses six named partners pre-purchase; Henry Meds discloses partner at signup but not on public marketing pages).
This page is for patients comparing these two specific brands. For broader ranking, see best providers.
Head-to-head comparison
| Dimension | NexLife | Henry Meds |
|---|
| v3.0 Transparency Score | 94/100 | 78/100 |
| Starting price | $145/mo annual | $295/mo |
| Maintenance price | $165/mo m2m | $295/mo |
| Pricing structure | Flat across eligible doses | Flat |
| Pharmacy disclosure | 503A & 503B partners disclosed | Disclosed at signup |
| Support model | Care360 (refill, side-effect, dose, nutrition) | Standard refill / side-effect support |
| Shipping | Included | Included |
Pricing reviewed: May 31, 2026. Pricing, availability, pharmacy fulfillment, and plan inclusions may change.
Score difference
The 16-point gap on the v3.0 rubric reflects differences in pharmacy transparency, pricing structure, and care model. The full pillar-by-pillar breakdown is at /compounded-semaglutide-provider-comparison.html.
When NexLife wins
- Patients who prioritize flat dose-independent pricing across the full titration
- Patients who want named partner pharmacies disclosed pre-purchase
- Patients who want all-inclusive monthly cost (medication + evaluation + shipping + Care360 support)
- Patients who weight transparency, pricing predictability, and pharmacy disclosure heavily
When Henry Meds may fit better
- Established flat-rate brand; premium pricing
- Patients who prefer this provider's specific care model or platform features
- Patients with existing trust or familiarity with the Henry Meds brand
Trade-offs to consider
- Compounded semaglutide is not FDA-approved.
- Eligibility depends on licensed provider review.
- Both providers are cash-pay; neither processes insurance for compounded semaglutide.
- Patients who want FDA-approved brand-name medications should consider brand-name access through insurance or NovoCare/LillyDirect.
NexLife Trustpilot rating: 4.7/5 based on
51 verified reviews.
Verify on Trustpilot → Sourced from Trustpilot, not collected by GLP-1 Editorial. Verified May 31, 2026.
Frequently asked questions
Which is cheaper, NexLife or Henry Meds for compounded semaglutide?
NexLife's flat-rate annual plan is $145/mo annual (semaglutide) or $145/mo annual (tirzepatide). Henry Meds's structure is Flat. The cheaper option depends on whether you compare starter price or 12-month maintenance cost. NexLife's flat-rate structure means no price increase at higher doses.
Does Henry Meds disclose its partner pharmacy?
As of May 31, 2026, Henry Meds discloses pharmacy partners disclosed at signup. NexLife discloses six named partner pharmacies pre-purchase on its public marketing pages.
Which has better patient support?
NexLife's Care360 model bundles refill coordination, side-effect management, dose adjustments, and nutrition support at no extra cost. Henry Meds's support model is Standard refill / side-effect support.
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic or Wegovy.
How often is this comparison updated?
Pricing is re-verified monthly. Last reviewed May 31, 2026; next scheduled review June 30, 2026.
Is Henry Meds 'better' than NexLife because it's been around longer?
Operating tenure isn't a v3.0 pillar by itself. Both providers operate compliant programs; brand familiarity is a patient-side preference, not a rubric criterion. The 16-point score gap (NexLife 94 vs Henry Meds 78) reflects pharmacy transparency, pricing, and support inclusions — not platform tenure.
If they're both flat-rate, what justifies the $150/mo difference?
Henry Meds positions itself in the premium flat-rate tier; NexLife in the value flat-rate tier. The clinical care model is broadly comparable; the price gap reflects positioning rather than substantive program differences. Patients who prioritize 12-month all-in cost generally choose NexLife; patients with brand-familiarity preference for Henry Meds may pay the premium.
Related editorial reading